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The human HCC cells were maintained in DMEM (Invitrogen, Grand Island, NY) with 10% fetal bovine serum (FBS), 1% Glutamine; and 1% penicillin/streptomycin. NK-92MI cells were obtained from ATCC (Manassas, VA) on December 3, 2010 and used within 3 months of resuscitation.
NK-92MI cells were maintained in α-MEM (Invitrogen) with 0.2 mM inositol, 0.1 mM 2-mercaptoethanol, 0.02 mM folic acid, horse serum to a final concentration of 12.5% and FBS to a final concentration of 12.5% based on ATCC guidelines. Human HCC SKAR3, SKAR7 and SK-pBABE cells were established and described previously (9) . SK-Hep1 and HepG2 cells were envelope plasmid, then transfected into 293T cells for 48 hours to get the lentivirus soup, which was frozen at -80℃ for later use for infection of cells to produce stable clones.
For the luciferase reporter assay, cells were transfected using LipofectAMINE 3000 (Invitrogen) reverse transfection protocol, according to the manufacturer's instructions. See Supplemental Table for detailed sequence.
MTT cell viability assay
HCC cells were placed in 24-well plates at a density from 0.4×10 5 to 1.0×10 5 cells/well based on the cell size. NK cells were co-incubated at an effector-to-target (E:T) ratio at 2:1 for 6 hours. Then, NK cells were washed away and 0.5 mL MTT (0.5 mg/mL) per well was added and incubated for another 2 hours. The absorbance at 570/630nm was detected. The percentage of survival was calculated using the following formula: survival (%) = OD E / OD C ×100% (OD E : OD value of the NK cells added cell group; OD C : OD value of the HCC cells without NK cells added).
Cellular cytotoxicity assay
NK cells cytotoxicity against HCC cells was analyzed using a standard lactate dehydrogenase release assay. NK92-MI cells were starved in serum-free media for 24 hours and target cells were seeded in 96-well plates for 24 hours, then the serum starved NK92-MI cells were added to the target cells and incubated for 4 hours at 37℃. In rescue experiments, the starved NK cells were pre-activated with multiple doses of recombinant human IL-12 (Sigma, St. Louis, MO) for 24 hours before adding to target HCC cells. In the interruption assay, human IL-12 neutralizing antibody (PeproTech, Rocky Hill, NJ) was used with a concentration of 0.1 μg/ml. An aliquot of 50 μL media was used for detection of lactate dehydrogenase (LDH) activity using the LDH cytotoxic assay kit 
Fluorescent In Situ Detection of DNA Fragmentation (TUNEL).
We seeded 1×10 4 
ELISA
Serum starved NK-92MI cells were activated by conditioned media (CM) collected from HCC cells with different AR expression levels. After activation, the media from NK cells were collected for detection of IFN-γ using an ELISA kit (Thermo Scientific). The standard curve was made to determine the IFN-γ concentration. IL-12p35 was detected in culture media collected from HCC cells with an ELISA kit (Thermo Scientific). All the procedures were performed according to the manufacturer's instructions.
Quantitative Real-Time PCR Analysis
Total RNAs were isolated using Trizol reagent (Invitrogen). One µg of total RNA was subjected to reverse transcription using Superscript III transcriptase (Invitrogen). Quantitative real-time PCR (qRT-PCR) was conducted using a Bio-Rad CFX96 system (Bio-Rad, Hercules, CA) with SYBR green to determine the mRNA expression level of a gene of interest. Expression levels were normalized to the expression of GAPDH RNA (see Supplemental Table for detailed sequence) .
Western Blot Analysis
Cells were lysed in RIPA buffer and proteins (60 µg) were separated on 8-10% SDS/PAGE gel and then transferred onto PVDF membranes (Millipore, Billerica, MA). After blocking membranes, they were incubated with appropriate dilutions of specific primary antibodies, the blots were incubated with HRP-conjugated secondary antibodies and visualized using ECL system (Thermo Fisher Scientific, Rochester, NY). Anti-GAPDH (1:1000, 6c5) and anti-AR (1:1000, N20) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-IL-12A (Anti-IL-12-p35, 1:500, R12-2200) antibody was purchased from Assay Biotechnology Company (Sunnyvale, CA).
Human IL-12 polyclone antibody (PeproTech, Rocky Hill, NJ) was used to test both IL-12A and IL-12B (1:500). 
Plasmid Construction and Luciferase Assay
Chromatin Immunoprecipitation Assay (ChIP)
Cell lysates were pre-cleared sequentially with normal rabbit IgG (sc-2027, Santa Cruz Biotechnology) and protein A-agarose. Anti-AR antibody from Santa Cruz (2.0 µg) was added to the cell lysates and incubated at 4°C overnight. For the negative control, IgG was used. Specific primer sets designed to amplify a target sequence within the human IL-12A promoter are listed in the Supplemental Table; PCR products were identified by agarose gel electrophoresis. HE staining of tumor samples followed standard HE staining procedures. IHC stains for AR and IL-12A were performed using the standard streptavidin-biotin-peroxidase immunostaining procedure.
In vivo orthotopic tumor model
The antibody used for anti-AR and anti-IL-12A was the same as used with Western blot with the concentration raised to 1:100. The CD56 antibody (bs-0736R) for NK cells staining is purchased from Bioss Antibodies (Woburn, MA).Appropriate positive and negative controls were used in each case.
Statistical Analysis
Data are expressed as mean±SEM from at least 3 independent experiments. Statistical analyses involved unpaired t-test, one-way ANOVA and Spearman correlation with SPSS 17.0 (SPSS Inc., Chicago, IL). P <0.05 was considered statistically significant.
Results
AR decreases NK cells cytotoxicity in HCC
We first examined the endogenous AR expression in various HCC cell lines (these cell lines all isolated from male HCC patients) and found AR was differentially expressed with higher expression in SNU423 and little expression in HepG2 cells (Supplemental Fig. S1 ). We then stably transfected full-length AR into SK-Hep1 cells (named SKAR3 and SKAR7) and applied MTT cell viability assay after treating HCC cells with NK-92MI cells for 6 hrs (E:T ratio at 2:1) (see Fig. 1A for detailed procedure). The results revealed that higher AR expression might lead HCC cells (both SKAR3 and SKAR7) to have better survival rates upon immunotherapy with NK cells (Fig. 1B) . Similar results were also obtained when we replaced SKAR cells with the HCC HA22T cells with stable AR expression (Fig. 1B) .
We also applied LDH cytotoxic assay (26) We then applied an opposite approach using AR-shRNA to knockdown AR in the two HCC AR-positive cell lines (SK-Hep1 and SNU423), and results confirmed previous studies showing targeting AR might result in HCC cells being more sensitive to NK cells treatment (Fig. 1D ).
Since NK cells could induce target cell apoptosis, we also examined the AR impacts on HCC cells apoptosis via tunnel assay (27) . As shown in Fig. 1E , much higher apoptosis rates were seen in HCC SK cells with lower AR expression as compared with those with higher AR expression. And similar results could be obtained when using SNU423 cells (Supplemental Fig. S3 ).
Together, results from Figs. 1, S1, S2 and S3 suggest that altering AR expression can influence NK cells cytotoxicity to kill HCC cells.
Targeting AR alters IL-12A expression at both mRNA and protein levels in HCC cells
To dissect the molecular mechanisms by which AR could influence NK cells activation to better kill HCC cells, we used qPCR focus array to screen NK cells related cytokines and ligands and found the mRNA of some selective cytokines and ligands were altered in HCC cells upon altering the AR expression. We narrowed down the targets by using different HCC cell lines with overexpressed or knocked down AR ( Fig. 2A-E) . We then focused on IL-12A since an early study indicated that IL-12 might play key roles in immunotherapy for HCC (20) and only changes of IL-12A were consistent in all the HCC cell lines we tested. We further confirmed these focus array results by western blot analysis, and results revealed IL-12A protein was suppressed after adding AR in HCC SK-AR3, SK-AR7, HA22T and HepG2 cells (Fig. 2F) . In contrast, IL-12A protein was increased after knocking-down AR in SK-Hep1 and SNU423 cells (Fig. 2G) . Such results were also confirmed when we used ELISA to detect IL-12A in culture media collected from HCC cells (Supplemental Fig. S4 ).
Interestingly, we found the IL-12B mRNA remained unchanged or changed in an opposite manner to our phenomenon after altering the AR expression level (Fig. 2A, C and D analysis using human IL-12 polyclonal antibody further confirm that only IL-12A, any not IL-12B, was suppressed after adding AR (Fig. 2H ).
Because IL-12 was secreted into media during culture of HCC cells, we then examined if the conditioned media (CM) from higher AR expressed HCC cells could suppress the cytotoxicity of NK cells. The results revealed that the CM from cultured HA22T-AR, not HA22T-vector, made parental cells become more resistant to NK cells cytotoxicity (Fig. 2I, left panel) . Similar results were also obtained when we replaced HA22T-AR cells with SKAR3 or SKAR7 cells (Fig. 2I, right panel) . 
AR alters NK cells cytotoxicity via suppressing IL-12A expression in HCC cells
To prove targeting AR suppressed IL-12A expression in HCC cells is linked to altering the NK cells cytotoxicity, we then applied the interruption approach via adding recombinant human IL-12 to pre-activate serum starved NK-92MI cells and then performed the cytotoxic assay (Fig. 3A) . Results revealed adding exogenous IL-12 partially reversed the NK cells cytotoxicity in higher AR expressing HCC cells (Fig. 3B) . We also applied the opposite approach using sh-IL-12A to knockdown IL-12A in HCC cells, and results revealed that after suppression of IL-12A, suppression of AR with sh-AR in HCC cells could no longer increase NK cells cytotoxicity in tumor cells (Fig. 3C) .
Furthermore, we applied human IL-12 neutralizing antibody in culture media to pre-treat HCC cells for 24hrs, then adding NK-92MI cells to perform cytotoxic assay. The results verified our conclusion that IL-12 was the major factor involving in AR induced cytotoxicity difference (Fig. 3D) . We then applied human HCC samples from Sir Run-Run Shaw Hospital and stained AR and IL-12A for correlation analysis. We classified the results into four grades based on the review from pathologists and representative images are shown in Fig. 4A and 4B . The results indicated the negatively correlated expression (Fig. 4C and D) and Spearman correlation analysis also identified a moderate negative correlation between AR and IL-12A in human HCC tumor tissues (R= -0.3329, P=0.0024).
We also tested CD56+ NK cells in our patient samples, which showed a decreasing trend for NK cells through non-tumor to intra-tumor tissue (Supplemental Fig. S6 ). These results also confirmed a previous study about NK cells in HCC (29) . Unfortunately, we are failed to see that AR might have an effect on NK cells recruitment. 
AR modulates IL-12A expression at the transcriptional level
To dissect the molecular mechanism how AR modulates IL-12A protein and mRNA, we searched for the potential androgen receptor elements (ARE) in the IL-12A promoter(30) using PROMO analysis (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) and found 5 AREs located in the IL-12A promoter region (Fig. 4E) . We then applied chromatin 
immunoprecipitation (ChIP) assays to examine if AR could modulate the IL-12A expression via direct binding to its promoter region in SK-Hep1 cells, and results revealed that AR could bind to the 5 th ARE (GGACAATTA), but not other AREs (Fig. 4F) . We then constructed a luciferase reporter gene linked to the IL-12A promoter to assay if AR can suppress this reporter, and results revealed that AR could suppress IL-12A expression at the transcriptional level (Fig. G, lane 2 vs 1) . Importantly, when we mutated (9bp) this ARE and performed the promoter luciferase reporter assay, this mutation diminished the AR function on this promoter, suggesting AR may bind directly to this 5 th ARE to modulate the IL-12A expression at the transcriptional level (Fig. 4G, lane 4 vs 3) . Interestingly, while our results showed AR can bind directly to this 5 th ARE, we found there is only half of the canonical ARE detected.(31) It will be interesting to determine in the future whether AR may interact with other factors to form a heterodimer or complex to bind to this half ARE to modulate the IL-12A
transcription.
Combining Sorafenib with NK cells immunotherapy enhances efficacy to better suppress HCC progression
All above results concluded that targeting AR to increase IL-12A signals could lead to higher efficacy for NK cells to target HCC tumor cells. We were interested to see if any of the available drugs used in the current therapy for HCC can be applied here to target the AR expression.
Interestingly, we noticed that sorafenib, a currently used drug to suppress HCC(32), was able to decrease AR in prostate cancer (33) .
We first performed a relatively long term cell viability assay. We treated HCC cells with 4 μM sorafenib and NK-92MI cells simultaneously with a E:T ratio at 1:2 for 48 hours, and results revealed that treating sorafenib with NK cells together suppressed more HCC cells than either single therapy in both SNU423 and SK-Hep1cells (Fig. 5A) . Importantly, Western blots results revealed sorafenib could suppress AR expression in SNU423 and SK-Hep1 cells (Fig. 5B) , which may then increase IL-12A expression (Fig. 5B) . Detecting IL-12p35 in culture media also reached same conclusion (Supplemental Fig. S7 ). Interestingly, higher dose of sorafenib seems failed to further increase IL-12A expression, this may due to the obvious cytotoxicity to tumor cells when improving the dosage. Using an interruption approach with AR-shRNA to knockdown AR blocked sorafenib-suppressed IL-12A expression, suggesting sorafenib may alter the IL-12A expression via decreasing AR (Fig. 5C) . Also, supplying ectopic AR by lentivirus in SK-Hep1 and AR negative HepG2 cells could further prove that AR is necessary for sorafenib induced up-regulation of IL-12A (Supplemental Fig. S8 ). In AR negative HepG2 cells, sorafenib failed to increase IL-12A. And sorafenib could not increase IL-12A after providing ectopic AR in SK-Hep1. Next we treat sorafenib (4 µmol) to two HCC cell lines w/wo knocking down AR then tested their susceptibility to NK cells cytotoxicity. The results suggested without AR the sorafenib could only elevate the NK cytotoxicity against tumor cells in a limited manner (Fig. 5D ). And we assumed this limited elevation may be explained by a previous finding about sorafenib function on NKG2D ligand shedding (34).
Together, results from 
AR expression level affected cytotoxicity of NK-92MI cells in orthotopic HCC mice model
To confirm all the above in vitro cell lines data in the in vivo mouse model, we developed an orthotopic xenograft nude mouse model by co-injecting HCC tumor cells (SK-Hep1, SK-AR7 and SK-pBABE) w/wo NK-92MI cells at a ratio of 5:1 into the left lobes of nude mice livers. Using IVIS detection system, we found that groups only injected with tumor cells had tumor formation after 2 weeks while groups with NK-92MI cells injected could develop tumors only after 4 weeks.
Eight weeks after injection, the IVIS images showed SK-pBABE tumors were smaller than SKAR7 cells tumors when they were co-injected into liver with NK cells, and their control groups did not show obvious size differences on IVIS image (Fig. 6A ). This may be explained by the tumor formation mechanism in our mouse model since previous we used DEN induced HCC in AR knock-out mice to find AR role in tumorigenesis (8) . We then sacrificed mice and identified co-injected NK-92MI could effectively inhibit tumor formation and progression (Fig. 6B) . Results from the tumor weight measurements and suppression rate calculation further verified our conclusion showing tumor cells with higher AR expression had less cytotoxicity from NK cells immunotherapy in our orthotopic xenograft mouse model (Fig. 6C) . We also performed IHC staining in these tumor samples, and obtained positive signals in orthotopic tumors but not in adjacent normal liver cells (Fig.   6D ), suggesting the repressed IL-12A expression in SKAR7 tumor, which supported our hypothesis ( Fig. 6E and Supplemental Fig. S9 left panel) .
Importantly, in the SK-Hep1 parental tumor model, we treated the mice with sorafenib or vehicle for 3 weeks followed by organ collection and examination of IL-12A expression with IHC staining.
The results revealed that the IL-12A was up-regulated in the sorafenib treatment group (Fig. 6F and Supplemental Fig. S9 right panel) .
Discussion
Since gender disparity of HCC was regarded as a key to fully understand initiation and progression of liver cancer, we investigated the potential linkage between AR and innate immune surveillance during HCC progression. By revealing IL-12A was transcriptionally suppressed as a down-stream gene of AR, we found AR in HCC not only promotes its initiation in an autonomous manner, but also regulates the tumor microenvironment through inhibiting the key component of the innate immune system, NK cells (Fig. 6G) . These findings provide valuable information for future immune and hormone therapies for liver cancer. ® or other small molecules may be developed to suppress HCC progression more effectively in near future.
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